Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Enzalutamide,EnzaStudy001,2021,USA,MDV,350,72,0.5,99.5,27.5,35,85,70,10,25,35,30,60,25,10,5,15,30,35,20,8,5,12,7,5,10,15,Docetaxel,Carboplatin,None,None,0,0,0,10,15,25,15,45,40,60,3
Enzalutamide,EnzaStudy002,2022,Canada,Claim Database,420,75,0.3,99.7,28.1,38,82,72,8,22,38,32,58,27,9,6,13,28,37,22,9,6,13,8,6,11,16,Docetaxel,Carboplatin,None,None,0,0,0,11,16,26,16,46,38,62,4
Enzalutamide,EnzaStudy003,2023,UK,MDV,280,70,0.7,99.3,26.8,32,88,68,12,28,32,28,62,23,11,4,17,32,33,18,7,4,11,6,4,9,14,Docetaxel,Carboplatin,None,None,0,0,0,9,14,23,14,44,42,58,2
